How White was paid
$1M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Mark WhiteChief Executive Officer/Chief Financial Officer | $318,000 | $220,000 | $490,470 | — | $1,028,470 |
| David Owens, M.D.Chief Medical Officer | — | — | $661,452 | $15,600 | $873,140 |
| Michael NketiahSenior Vice-President of Quality, Clinical and Regulatory | $158,173 | — | — | — | $158,173 |
| Carolyn SheltonSenior Vice-President of Quality, Clinical and Regulatory | $93,500 | $20,000 | $174,534 | — | $288,534 |
What changed and why
- $1M$1,028,470 was Mark White’s 2024 total compensation, up from $679,815 in 2023.
- $220K$220,000 bonus was awarded to White in 2024, payable during 2025.
- $490K$490,470 was reported for White’s combined stock/option awards in 2024.
- $196K$196,088 was David Owens’s 2024 board fee and consulting compensation.
- $661K$661,452 was Owens’s combined stock/option awards in 2024.
- $20,000$20,000 bonus was earned by Carolyn Shelton in 2024, payable during 2025.
Other Nexalin Technology proxy statements
- 2026 proxy statement
Mark White paid $839,476 (-18% on the year).
Filed Jul 10, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.